Establishment Labs Holdings Inc. $ESTA Stake Increased by Tyro Capital Management LLC

Tyro Capital Management LLC raised its position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) by 1.0% in the third quarter, Holdings Channel reports. The firm owned 1,077,456 shares of the company’s stock after acquiring an additional 10,735 shares during the quarter. Establishment Labs accounts for 16.4% of Tyro Capital Management LLC’s holdings, making the stock its biggest holding. Tyro Capital Management LLC’s holdings in Establishment Labs were worth $44,165,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of ESTA. CenterBook Partners LP bought a new position in shares of Establishment Labs in the second quarter worth approximately $16,204,000. Viking Global Investors LP bought a new stake in shares of Establishment Labs during the second quarter valued at approximately $14,669,000. Woodson Capital Management LP raised its holdings in Establishment Labs by 113.3% in the 3rd quarter. Woodson Capital Management LP now owns 480,000 shares of the company’s stock worth $19,675,000 after acquiring an additional 255,000 shares during the last quarter. Soleus Capital Management L.P. bought a new position in Establishment Labs in the 2nd quarter valued at approximately $9,050,000. Finally, Garnet Equity Capital Holdings Inc. bought a new position in Establishment Labs in the 2nd quarter valued at approximately $7,062,000. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Price Performance

Shares of NASDAQ:ESTA opened at $69.06 on Tuesday. The company has a quick ratio of 2.00, a current ratio of 3.04 and a debt-to-equity ratio of 10.51. The stock has a market capitalization of $2.02 billion, a PE ratio of -39.69 and a beta of 0.91. The firm’s 50 day moving average price is $70.81 and its 200-day moving average price is $60.03. Establishment Labs Holdings Inc. has a twelve month low of $26.56 and a twelve month high of $83.31.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Tuesday, February 24th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.13. Establishment Labs had a negative net margin of 24.19% and a negative return on equity of 201.79%. The company had revenue of $64.62 million during the quarter, compared to analyst estimates of $63.80 million. During the same period in the previous year, the business posted ($1.19) earnings per share. The firm’s quarterly revenue was up 45.2% compared to the same quarter last year. Equities research analysts expect that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Analyst Ratings Changes

ESTA has been the subject of a number of research analyst reports. JPMorgan Chase & Co. lifted their target price on Establishment Labs from $71.00 to $80.00 and gave the stock an “overweight” rating in a report on Wednesday, December 17th. Stephens upped their price target on Establishment Labs from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Wednesday, February 25th. Needham & Company LLC increased their price objective on Establishment Labs from $84.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, February 24th. Citigroup lifted their price objective on Establishment Labs from $62.00 to $75.00 and gave the stock a “neutral” rating in a report on Thursday, December 11th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research report on Monday, December 29th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $87.00.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.